Review
Version 3
Preserved in Portico This version is not peer-reviewed
COVID-19 Virus Infection and Transmission are Observably Less in Highly Dengue-endemic Countries: Can Dengue Vaccines be “Repurposed” to Prevent COVID-19?
Version 1
: Received: 2 April 2020 / Approved: 3 April 2020 / Online: 3 April 2020 (15:48:36 CEST)
Version 2 : Received: 13 April 2020 / Approved: 14 April 2020 / Online: 14 April 2020 (08:49:03 CEST)
Version 3 : Received: 2 May 2020 / Approved: 5 May 2020 / Online: 5 May 2020 (03:00:34 CEST)
Version 2 : Received: 13 April 2020 / Approved: 14 April 2020 / Online: 14 April 2020 (08:49:03 CEST)
Version 3 : Received: 2 May 2020 / Approved: 5 May 2020 / Online: 5 May 2020 (03:00:34 CEST)
A peer-reviewed article of this Preprint also exists.
Abstract
Global severity maps of ongoing dengue epidemic and COVID-19 pandemic do not overlap. Countries with high dengue endemicity (>1.5 million cases/year) are observably less hit by COVID-19 in terms of infection, transmission and mortality. Based on non-overlap of dengue and COVID-19 severity maps and evidence of SARS-CoV-2 serological cross-reactions with dengue, we wonder whether immediate immunization of susceptible populations in Europe, North America and Asia (China, Iran) with available live-attenuated dengue vaccines, will cue the anti-viral immune response to thwart COVID-19 (viral interference). Risk of developing post-vaccination “Antibody-dependent Enhancement” is low as dengue is not endemic in the aforesaid regions.
Keywords
Dengue; COVID-19; SARS-CoV-2; epidemiology; infection; mortality; cross-protection; Dengue vaccine; ELISA; Dengvaxia
Subject
LIFE SCIENCES, Virology
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (3)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
Commenter: Subhajit Biswas
Commenter's Conflict of Interests: Author
Commenter:
The commenter has declared there is no conflict of interests.
You can read our analysis online, and let us know your comments.
Title of publication: Computational modelling predicts that Dengue virus antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID-19 severity?
(Link: https://osf.io/dutx4)
On the basis of our observations that COVID-19 and Dengue severity maps do not tend to overlap and the fact that serological cross-reactivity has been reported for COVID-19 antibodies with Dengue antigen (s), together with results from our computational studies, we are of opinion that serology-based diagnosis needs to be complemented with NAT/virus antigen detection-based tests for definitive diagnosis/sero-surveillance of either disease in regions where both of these viruses are now co-existent.
The commenter has declared there is no conflict of interests.
Please read our latest findings:
Dengue antibodies can cross-react with SARS-CoV-2 and vice versa-Antibody detection kits can give false-positive results for both viruses in regions where both COVID-19 and Dengue co-exist.
https://www.medrxiv.org/content/10.1101/2020.07.03.20145797v1.article-metrics
Authors.